OTCQX

CLEARDAY LIVING IMPLEMENTS SMART TOILET INNOVATION DESIGNED TO IMPROVE RESIDENT HEALTH

Retrieved on: 
Friday, February 16, 2024

Naples, FL, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Clearday Living, a business unit of Clearday (OTCQX CLRD) a long-term care provider and leader in cognitive care with a unique focus on innovation, has implemented the TrueLoo® smart toilet seat in select resident rooms at its Naples Florida Innovation Center. Use of this cutting-edge technology is another example of how Clearday Living is continually tapping into innovative ideas and products to improve the lives of residents in its Innovation Center. Clearday Living first tested TrueLoo® nearly a year ago in its community in Naples to utilize this new toilet technology from Toi Labs.

Key Points: 
  • Naples, FL, Feb. 16, 2024 (GLOBE NEWSWIRE) -- Clearday Living , a business unit of Clearday (OTCQX CLRD) a long-term care provider and leader in cognitive care with a unique focus on innovation, has implemented the TrueLoo® smart toilet seat in select resident rooms at its Naples Florida Innovation Center.
  • Use of this cutting-edge technology is another example of how Clearday Living is continually tapping into innovative ideas and products to improve the lives of residents in its Innovation Center.
  • Clearday Living first tested TrueLoo® nearly a year ago in its community in Naples to utilize this new toilet technology from Toi Labs .
  • The smart toilet seat helps identify abnormal waste patterns that often indicate health issues and may help reduce the risk and impact of certain chronic diseases or conditions.

Media Alert: BrainChip CEO Talks Successes and Momentum in the Latest Investor Podcast

Retrieved on: 
Thursday, February 15, 2024

In this fourth episode of BrainChip’s Quarterly Investor Podcast, Director of Global Investor Relations Tony Dawe presents these questions to Hehir across a range of topics including successes achieved during the past year, the latest product updates, and other various shareholder interests.

Key Points: 
  • In this fourth episode of BrainChip’s Quarterly Investor Podcast, Director of Global Investor Relations Tony Dawe presents these questions to Hehir across a range of topics including successes achieved during the past year, the latest product updates, and other various shareholder interests.
  • Among the topics covered in this podcast are:
    Achievements made by BrainChip in 2023 and what the company is doing to continue this positive momentum throughout 2024.
  • Emergent themes coming out of CES 2024 and how BrainChip is poised to address them.
  • “The BrainChip Investor Podcast is an ideal venue for me to communicate the company’s successes, milestones and plans based on input direct from our investment community.

Pinnacle Bankshares Corporation Announces Record High 2023 Earnings

Retrieved on: 
Thursday, February 15, 2024

Net income for the year ended December 31, 2023 was a record high $9,762,000, or $4.45 per basic and diluted share.

Key Points: 
  • Net income for the year ended December 31, 2023 was a record high $9,762,000, or $4.45 per basic and diluted share.
  • Fourth Quarter & 2023 Highlights include the following:
    Record High 2023 Net Income of $9,762,000 surpassed the previous annual record high net income of $8,242,000 achieved in 2022.
  • “We are very pleased to report Pinnacle’s record high earnings for 2023,” stated Aubrey H. Hall, III, President and Chief Executive Officer for both the Company and the Bank.
  • Pinnacle Bankshares Corporation is a locally managed community banking organization based in Central and Southern Virginia.

Media Alert: BrainChip Demonstrates Human Behavior Detection at IFS Direct Connect 2024

Retrieved on: 
Thursday, February 15, 2024

BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first commercial producer of ultra-low power, fully digital, event-based, neuromorphic AI, will host an exhibit demonstrating human behavior AI at IFS Direct Connect 2024 at the San Jose McEnery Convention Center in San Jose, California, February 21.

Key Points: 
  • BrainChip Holdings Ltd (ASX: BRN, OTCQX: BRCHF, ADR: BCHPY), the world’s first commercial producer of ultra-low power, fully digital, event-based, neuromorphic AI, will host an exhibit demonstrating human behavior AI at IFS Direct Connect 2024 at the San Jose McEnery Convention Center in San Jose, California, February 21.
  • BrainChip will spotlight Akida’s neuromorphic advantage, emphasizing the scalability of its IP within Intel’s Open System Foundry.
  • Among the highlights of IFS Direct Connect is a demonstration of NVISO Group AI Human Behavioral Software and BrainChip’s Akida™ neuromorphic compute.
  • “We look forward to showcasing our latest collaborations, IP achievements and AI capabilities to Intel Foundry Services alliance partners, customers, media and analysts joining us at IFS Direct Connect 2024,” said Sean Hehir, CEO of BrainChip.

Remark Holdings Announces Listing on OTC Pink Market

Retrieved on: 
Thursday, February 15, 2024

LAS VEGAS, Feb. 15, 2024 /PRNewswire/ -- Remark Holdings, Inc. (OTC: MARK), a diversified global technology company with leading artificial intelligence ("AI") solutions and video analytics, today announced that its shares of common stock (the "Shares"), began trading on the OTC Pink Market under the symbol MARK effective at the opening of trading on Wednesday, February 14, 2024.

Key Points: 
  • LAS VEGAS, Feb. 15, 2024 /PRNewswire/ -- Remark Holdings, Inc. (OTC: MARK), a diversified global technology company with leading artificial intelligence ("AI") solutions and video analytics, today announced that its shares of common stock (the "Shares"), began trading on the OTC Pink Market under the symbol MARK effective at the opening of trading on Wednesday, February 14, 2024.
  • Existing shareholders of Remark Holdings, Inc. ("Remark") will now find the Shares quoted on the OTC Pink Market and freely tradable without any further action needed.
  • Though the Shares are currently traded on the OTC Pink Market, Remark is actively working towards an OTCQX listing to further improve investor access and liquidity.

How Supply & Demand is Likely Driving the Uranium Market to Reach a 16-Year Peak This Year

Retrieved on: 
Wednesday, February 14, 2024

PALM BEACH, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Experts predict that the global uranium market is likely to reach a 16 year peak in 2024.

Key Points: 
  • PALM BEACH, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Experts predict that the global uranium market is likely to reach a 16 year peak in 2024.
  • Toronto-listed Cameco is expected to be the world's second largest uranium producer this year after Kazatomprom.
  • The objective of the 2024 program is the discovery of uranium mineralization associated with conductive electromagnetic (EM) anomalies.
  • “We are incredibly excited to be starting the preparations for our maiden drill program, a key milestone for the company.

Microbix Reports Record Results for Q1 Fiscal 2024

Retrieved on: 
Wednesday, February 14, 2024

MISSISSAUGA, Ontario, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its first quarter of fiscal 2024 ended December 31, 2023 (“Q1”), with record quarterly revenues and a record quarterly profit, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices, and material licensing revenues from its fully-funded program to revalidate and relaunch its approved drug, Kinlytic® urokinase (“Kinlytic”).

Key Points: 
  • MISSISSAUGA, Ontario, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, reports results for its first quarter of fiscal 2024 ended December 31, 2023 (“Q1”), with record quarterly revenues and a record quarterly profit, reflective of ongoing progress to increase sales from its diagnostic-test related ingredients and devices, and material licensing revenues from its fully-funded program to revalidate and relaunch its approved drug, Kinlytic® urokinase (“Kinlytic”).
  • Collectively, the resulting revenues of over C$ 8.4 million led to strong net earnings and set the stage for a record full-year fiscal 2024.
  • Antigen sales grew by 95% to $1,953,677 (Q1 F2023 - $1,003,608), while QAPs grew by 69% to $2,248,236 (Q1 F2023 - $1,333,503).
  • The above results led to a Q1 operating income and net income of $2,455,379 versus a Q1 2023 operating loss and net loss of ($1,299,262).

OTC Markets Group Welcomes CVW CleanTech Inc. to OTCQX

Retrieved on: 
Wednesday, February 14, 2024

NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced that CVW CleanTech Inc. (“CVW CleanTech” or the “Company”) (TSX-V: CVW; OTCQX: CVWFF) has qualified to trade on the OTCQX® Best Market.

Key Points: 
  • NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced that CVW CleanTech Inc. (“CVW CleanTech” or the “Company”) (TSX-V: CVW; OTCQX: CVWFF) has qualified to trade on the OTCQX® Best Market.
  • CVW CleanTech upgraded to OTCQX from the Pink® market.
  • CVW CleanTech Inc. begins trading today on OTCQX under the symbol “CVWFF.” U.S. investors can find current financial and other relevant disclosures, and Real-Time Level 2 quotes for the Company, on www.otcmarkets.com .
  • “We are pleased to begin trading on the OTCQX Market in New York.

Antibe Reports Q3 2024 Interim Financial and Operating Results

Retrieved on: 
Wednesday, February 14, 2024

Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2023.

Key Points: 
  • Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage biotechnology company leveraging its hydrogen sulfide platform to target pain and inflammation, has filed its financial and operating results for the fiscal quarter ended December 31, 2023.
  • “The results of November’s successful PK/PD study have empowered us to make considerable enhancements to the Phase II trial,” commented Dan Legault, Antibe’s CEO.
  • General and Administrative Expenses: General and administrative expenses were $2.3 million, compared to $2.2 million in fiscal Q3 2023.
  • The Company’s unaudited fiscal Q3 2024 condensed interim financial statements and MD&A are available on SEDAR.

Tri-County Financial Group, Inc. Reports Fourth Quarter 2023 Financial Results

Retrieved on: 
Tuesday, February 13, 2024

MENDOTA, Ill., Feb. 13, 2024 /PRNewswire/ -- Tri-County Financial Group, Inc. (The Company) (OTCQX: TYFG) today announced financial results for the fourth quarter of 2023.

Key Points: 
  • MENDOTA, Ill., Feb. 13, 2024 /PRNewswire/ -- Tri-County Financial Group, Inc. (The Company) (OTCQX: TYFG) today announced financial results for the fourth quarter of 2023.
  • Net income for the fourth quarter of 2023 was $2.3 million ($0.94 per share), compared to $2.3 million ($0.92 per share) during the fourth quarter of 2022.
  • The net interest margin was 3.02% for the fourth quarter of 2023, compared to 3.27% for the fourth quarter of 2022.
  • Non-interest expense was $11.6 million during the quarter ended December 31, 2023, compared to $10.2 million for the fourth quarter of 2022, an increase of $1.4 million, or 14%.